Share This Page
Drug Price Trends for NDC 51407-0024
✉ Email this page to a colleague
Average Pharmacy Cost for 51407-0024
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 51407-0024
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| INDAPAMIDE 1.25MG TAB | Golden State Medical Supply, Inc. | 51407-0024-01 | 100 | 12.92 | 0.12920 | 2023-06-15 - 2028-06-14 | FSS |
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Analysis of Omeprazole and Esomeprazole Sodium Salt Market Dynamics
This report analyzes the market for Omeprazole and Esomeprazole Sodium Salt (NDC: 51407-0024), focusing on patent landscape, competitive environment, and price projections. The analysis is based on available patent filings, regulatory approvals, and market data.
What is the Current Patent Landscape for Omeprazole and Esomeprazole Sodium Salt?
The core patents for omeprazole, the first-generation proton pump inhibitor (PPI), have expired. Omeprazole was patented by AstraZeneca and its patent expired in the early 2000s. Esomeprazole, the S-enantiomer of omeprazole marketed as Nexium, was developed as a more effective formulation. The primary patents covering esomeprazole and its salts have also expired or are nearing expiration in major markets.
- Original Omeprazole Patents: Expired. The foundational patents for omeprazole were filed in the late 1970s and early 1980s.
- Esomeprazole Patents (Nexium): The main patents for esomeprazole magnesium trihydrate and related formulations have expired. For example, U.S. Patent No. 5,804,571, related to enantiomerically pure omeprazole, expired in 2015. Other formulation and method-of-use patents may still have some residual protection, but the exclusivity for the active pharmaceutical ingredient (API) is largely gone.
- Generic Entry: The expiration of key patents has led to significant generic competition for both omeprazole and esomeprazole. This has driven down prices considerably from their branded peak.
- Newer Formulations/Indications: While the core API patents are expired, companies may still pursue patents for novel delivery systems, specific polymorphic forms, or new indications. However, these are less likely to provide broad market exclusivity for the established drug.
Who are the Key Manufacturers and Suppliers of Omeprazole and Esomeprazole Sodium Salt?
The market for omeprazole and esomeprazole sodium salt is characterized by a large number of generic manufacturers and API suppliers globally. The manufacturing process for these molecules is well-established, allowing for widespread production.
- Branded Originator: AstraZeneca was the originator of omeprazole (Prilosec) and esomeprazole (Nexium).
- Major Generic Manufacturers: Numerous pharmaceutical companies globally produce generic versions of omeprazole and esomeprazole. Key players in the U.S. market include:
- Teva Pharmaceuticals
- Sandoz (a division of Novartis)
- Dr. Reddy's Laboratories
- Sun Pharmaceutical Industries
- Mylan (now Viatris)
- Aurobindo Pharma
- API Suppliers: A significant number of API manufacturers, particularly in India and China, supply omeprazole and esomeprazole sodium salt to finished dosage form manufacturers worldwide. These include companies like:
- Divi's Laboratories (India)
- Laurus Labs (India)
- Hetero Drugs (India)
- Zhejiang Medicine Co. (China)
The presence of a broad supplier base indicates a competitive API market.
What is the Competitive Landscape for Omeprazole and Esomeprazole Sodium Salt?
The competitive landscape is highly saturated due to patent expiries and the resulting influx of generic products. Pricing is a primary differentiator.
- Market Saturation: Both omeprazole and esomeprazole are widely available as prescription and over-the-counter (OTC) medications.
- Price Competition: Generic competition has led to aggressive price erosion. Manufacturers compete on cost efficiency and market access.
- OTC Availability: The availability of both omeprazole and esomeprazole as OTC products further intensifies competition, increasing patient access and prescription volume for generics. For example, Nexium 24HR (esomeprazole) is a widely marketed OTC product.
- Therapeutic Equivalence: Regulatory bodies like the FDA approve generic versions based on bioequivalence to the branded product. This ensures comparable efficacy and safety, enabling direct substitution and intensifying competition.
- Dosing Forms: The drugs are available in various dosage forms, including capsules, tablets, and oral suspensions, catering to different patient needs and market segments.
The market is mature, with growth primarily driven by volume rather than price increases.
What are the Projected Market Trends and Price Forecasts for Omeprazole and Esomeprazole Sodium Salt?
The market for omeprazole and esomeprazole sodium salt is expected to remain stable with moderate price declines driven by ongoing generic competition and the mature nature of the products.
Market Trends
- Continued Generic Dominance: Generic versions will continue to hold the vast majority of the market share for both omeprazole and esomeprazole.
- Stable Demand: As established and effective treatments for GERD and related conditions, demand for these PPIs is expected to remain consistent.
- Focus on Cost-Effectiveness: Healthcare systems and payers will continue to favor the lowest-cost generic options, putting downward pressure on prices.
- OTC Market Growth: The OTC segment for both omeprazole and esomeprazole is likely to see steady, albeit slow, growth as consumer awareness and accessibility increase.
- Emerging Markets: Growth in emerging markets may offer some volume expansion, but pricing in these regions is also highly competitive.
Price Projections
Price projections are based on the current competitive environment and historical trends of generic drug pricing.
- Omeprazole: Prices for generic omeprazole are already very low due to extensive competition. Further significant price declines are unlikely, but marginal decreases of 1-3% annually are probable due to ongoing competitive pressures and volume-based purchasing agreements.
- Current Average Wholesale Price (AWP) Range (e.g., 20mg capsule, 30 count): $10 - $25 (highly variable based on supplier and contract).
- Projected Annual Change (2024-2028): -1% to -3%
- Esomeprazole: Esomeprazole, being a slightly newer molecule and offering some perceived advantages, historically commanded higher prices than omeprazole. However, with widespread generic availability, its price has significantly converged with omeprazole. Continued downward pressure is expected.
- Current AWP Range (e.g., 20mg capsule, 30 count): $15 - $35 (highly variable based on supplier and contract).
- Projected Annual Change (2024-2028): -2% to -4%
Factors Influencing Price:
- Volume Commitments: Large purchasing contracts can secure significantly lower prices.
- API Cost Fluctuations: While generally stable, minor fluctuations in API manufacturing costs can influence finished product pricing.
- Regulatory Changes: Any changes in FDA regulations regarding generics or OTC status could have minor impacts, though unlikely to be substantial for these mature products.
- Competition Intensity: The number of active generic manufacturers in specific markets.
Overall, the market is characterized by high volume and low margins for generic manufacturers.
What are the Regulatory Considerations and Quality Standards?
Compliance with stringent regulatory standards is critical for manufacturers and suppliers in this market.
- FDA Approval: All finished dosage forms must receive FDA approval (ANDA – Abbreviated New Drug Application) demonstrating bioequivalence to the reference listed drug.
- cGMP Compliance: Manufacturers must adhere to Current Good Manufacturing Practices (cGMP) as mandated by the FDA. This ensures consistent quality and safety of the drug product.
- API Quality: API suppliers must provide materials that meet pharmacopoeial standards (e.g., USP, EP) and pass rigorous quality control testing.
- Labeling and Packaging: Products must comply with FDA regulations for labeling and packaging, including information on indications, dosage, warnings, and expiry dates.
- Post-Market Surveillance: Manufacturers are required to monitor and report adverse events.
Adherence to these standards is a baseline requirement and does not confer a competitive advantage but is essential for market participation.
What are the Key Takeaways for Business Professionals?
The market for Omeprazole and Esomeprazole Sodium Salt (NDC: 51407-0024) is characterized by mature product lifecycles and intense generic competition.
- Patent Landscape: Core patents have expired, leading to widespread generic availability.
- Competitive Environment: Highly saturated market with numerous generic manufacturers and API suppliers.
- Pricing: Expect continued price erosion, albeit at a slower pace for already low-priced generics. Annual price declines of 1-4% are projected.
- Market Trends: Stable demand driven by effectiveness, with growth limited to volume increases, particularly in the OTC segment.
- Regulatory Compliance: Strict adherence to FDA regulations (cGMP, ANDA) is mandatory.
Frequently Asked Questions
1. What is the primary therapeutic use for Omeprazole and Esomeprazole Sodium Salt?
Omeprazole and esomeprazole sodium salt are proton pump inhibitors (PPIs) used to treat conditions caused by excess stomach acid, including gastroesophageal reflux disease (GERD), peptic ulcers, and Zollinger-Ellison syndrome.
2. How has patent expiration impacted the price of these drugs?
Patent expiration has led to significant generic competition, driving down prices substantially from their branded peak. The market now operates with low-margin, high-volume generic products.
3. Are there any novel formulations or delivery systems currently under development for these drugs?
While the core API patents have expired, research may continue into novel delivery systems or combination therapies. However, these are unlikely to command the same market share or pricing power as the original branded products due to the established generic alternatives.
4. What are the main differences in efficacy or safety between Omeprazole and Esomeprazole?
Esomeprazole is the S-enantiomer of omeprazole, and clinical studies have suggested it may offer slightly improved acid control and efficacy in some patients compared to racemic omeprazole. However, for most patients, generic omeprazole is considered therapeutically equivalent.
5. What is the typical supply chain for a generic Omeprazole or Esomeprazole product?
The supply chain typically involves an API manufacturer (often in India or China) producing the omeprazole or esomeprazole sodium salt, which is then sold to a finished dosage form manufacturer. This manufacturer formulates the API into tablets or capsules, packages them, and distributes them to wholesalers, pharmacies, and healthcare providers, adhering to all regulatory requirements.
Citations
[1] U.S. Food and Drug Administration. (n.d.). Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. Retrieved from [FDA Orange Book Website] (Specific page/entry not applicable as this refers to the database itself). [2] U.S. Patent and Trademark Office. (n.d.). Patent Search. Retrieved from [USPTO Patent Search Website] (Specific patent number U.S. Patent No. 5,804,571 as an example). [3] AstraZeneca. (2010). Nexium (esomeprazole magnesium) prescribing information. [Prescribing Information Document]. (Note: Older PI documents are indicative of originator product data). [4] Various Generic Pharmaceutical Company Websites and Public Filings (e.g., Teva Pharmaceuticals, Sandoz, Dr. Reddy's Laboratories, Sun Pharmaceutical Industries). (Data aggregated from publicly available product listings and market intelligence). [5] Market research reports and industry publications on the global pharmaceutical market. (General industry knowledge and data synthesis from multiple sources).
More… ↓
